- More and more countries are using Sputnik Light as a
standalone vaccine and as a universal booster, including against
Omicron variant.
MOSCOW, Dec. 21, 2021 /PRNewswire/ -- The Russian Direct
Investment Fund (RDIF, Russia's
sovereign wealth fund) today announced 7 million doses of Sputnik
Light booster against coronavirus have been shipped to Venezuela becoming the biggest one-time global
delivery of the one-shot vaccine.
Demand for Sputnik Light is increasing as more countries are
using it as a standalone vaccine and a universal booster for
other vaccines, including against the latest Omicron variant of
coronavirus.
Sputnik Light is based on human adenovirus serotype 26 (the
first component of Sputnik V). It has already been registered in
more than 20 countries as a standalone one-shot vaccine and a
universal booster to other vaccines (including in Argentina, UAE, Bahrain, Philippines, and San
Marino).
Recent preliminary study announced by Gamaleya Institute showed
that Sputnik Light as a booster significantly increases virus
neutralizing activity against Omicron. According to Gamaleya
Institute:
- Sputnik Light as a booster significantly increases virus
neutralizing activity against Omicron based on sera 2-3 months
after revaccination. Virus neutralizing activity against Omicron
2-3 months after a Sputnik Light booster in this preliminary
laboratory study is higher than VNA against the wild-type virus 6
months after Sputnik V vaccination. Based on these data the
expected efficacy of Sputnik V with Sputnik Light booster against
Omicron infection could be more than 80%, as Sputnik V showed
efficacy of more than 80% against wild-type virus 6 month after
vaccination.
- 100% of individuals revaccinated with Sputnik Light as a
booster developed neutralizing antibodies against Omicron and
demonstrated their high level 2-3 months after the
revaccination.
- Sputnik Light booster is expected to provide strong protection
against infection, severe disease and hospitalization by
Omicron.
- Sputnik Light booster is recommended to strengthen efficacy of
vaccines against Omicron. Heterologous boosting with Sputnik Light
is the solution to strengthen and lengthen the quickly waning
efficacy of many vaccines, including against Omicron, and extend
the booster protection period.
- Sputnik V standalone also induces robust neutralizing antibody
response to Omicron variant, which is further strengthened by
Sputnik Light booster.
- Sputnik V elicits strong and long-lasting T-cell response, and
as 80% of epitopes in the spike protein are not affected by the
mutations in the Omicron variant, Sputnik V is expected to provide
long-lasting protection against severe disease by Omicron. Sputnik
V's long-lasting T-cell immunity contributes to 80% efficacy
against Delta on months 6-8 compared with efficacy of less than 29%
demonstrated by certain mRNA vaccines after 6 months.
In Argentina, a combination of
Sputnik Light with other vaccines has demonstrated its
effectiveness as a universal booster inducing stronger antibody and
T-cell response compared to a two-shots homologous regimen. A
combination of Sputnik Light with vaccines produced by AstraZeneca,
Sinopharm, Moderna and Cansino, conducted in 5 provinces (City and
Province of Buenos Aires, as well
as Córdoba, La Rioja and San Luis) has demonstrated that each
"vaccine cocktail" combination with Sputnik Light provided higher
antibody titer on the 14th day after administering a second dose
when compared to original homogenous (same vaccine as first and
second dose) regimens of each of the vaccines.
Sputnik Light efficacy data:
- Sputnik Light has been proven to be safe and highly effective
by real-world vaccination data. In particular, data from the
Ministry of Health of Buenos Aires
(Argentina) has demonstrated
standalone efficacy of Sputnik Light between 78.6-83.7% among the
elderly (over 40,000 people of 60-79 years old), which is higher
than that of many two-dose vaccines.
- Findings by the Gamaleya Center based on data collected in
Moscow have demonstrated Sputnik
Light vaccine administered standalone has 70% efficacy against
infection from the Delta variant of coronavirus during the first
three months after vaccination. The vaccine is 75% effective among
subjects under the age of 60.
- Sputnik Light and Sputnik V were developed on the basis of a
safe and well-studied over 30 years technology and have not been
associated with rare serious side effects as myocarditis or
pericarditis.
Logo -
https://mma.prnewswire.com/media/1698158/Russian_Direct_Invest_Fund_Logo.jpg